Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge

Publisher： Karger

E-ISSN： 1662-6575|7|1|277-284

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.7, Iss.1, 2014-04, pp. : 277-284

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-10 ,pp. : 586-591

Karger

Access to resources Recommend Favorite

Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements

By  

Acta Haematologica, Vol. 121, Iss. 1, 2009-03 ,pp. : 19-20

Karger

Access to resources Recommend Favorite

Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

Autoimmune Disorders in Two Patients with Myelodysplastic Syndrome and 5q Deletion

By  

Acta Haematologica, Vol. 113, Iss. 2, 2005-03 ,pp. : 146-149

Karger

Access to resources Recommend Favorite

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 115, Iss. 5, 2015-05 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite